JP2014530846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530846A5 JP2014530846A5 JP2014536349A JP2014536349A JP2014530846A5 JP 2014530846 A5 JP2014530846 A5 JP 2014530846A5 JP 2014536349 A JP2014536349 A JP 2014536349A JP 2014536349 A JP2014536349 A JP 2014536349A JP 2014530846 A5 JP2014530846 A5 JP 2014530846A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- oxymetazoline
- brimonidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 17
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical group CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 7
- 229960001528 oxymetazoline Drugs 0.000 claims 7
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 6
- 229960003679 brimonidine Drugs 0.000 claims 6
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 4
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 4
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims 4
- 230000001815 facial effect Effects 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 3
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 2
- 229960002342 mephentermine Drugs 0.000 claims 2
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 claims 2
- 229960005192 methoxamine Drugs 0.000 claims 2
- 229960005016 naphazoline Drugs 0.000 claims 2
- 229960001802 phenylephrine Drugs 0.000 claims 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229960000337 tetryzoline Drugs 0.000 claims 2
- 229960000833 xylometazoline Drugs 0.000 claims 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 229960001094 midodrine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548844P | 2011-10-19 | 2011-10-19 | |
| US61/548,844 | 2011-10-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530846A JP2014530846A (ja) | 2014-11-20 |
| JP2014530846A5 true JP2014530846A5 (enExample) | 2015-11-26 |
Family
ID=47631462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536349A Pending JP2014530846A (ja) | 2011-10-19 | 2012-10-12 | ホスホジエステラーゼ５型阻害薬の全身使用に伴う顔面潮紅の軽減方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9744168B2 (enExample) |
| EP (1) | EP2768502A2 (enExample) |
| JP (1) | JP2014530846A (enExample) |
| KR (1) | KR20140091543A (enExample) |
| CN (1) | CN103889417A (enExample) |
| AU (1) | AU2012324543B2 (enExample) |
| BR (1) | BR112014009210A2 (enExample) |
| CA (1) | CA2850273A1 (enExample) |
| IL (1) | IL231820A0 (enExample) |
| MX (1) | MX2014004383A (enExample) |
| PH (1) | PH12014500783A1 (enExample) |
| RU (1) | RU2014119879A (enExample) |
| WO (1) | WO2013057579A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| CA2951725C (en) * | 2014-06-11 | 2022-06-07 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| WO2018065546A1 (en) * | 2016-10-07 | 2018-04-12 | Micreos Human Health B.V. | Vasoconstricitve and antibacterial combination treatment for rosacea |
| KR102122980B1 (ko) * | 2018-12-28 | 2020-06-18 | 한국프라임제약주식회사 | 들깨 잎 추출물을 유효성분으로 함유하는 갱년기 관련 안면홍조 완화용 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| DE2436882A1 (de) | 1974-07-29 | 1976-02-19 | Schering Ag | Neue oxyphenylbutazon-derivate und ihre herstellung |
| DE2632678C2 (de) | 1976-07-16 | 1986-02-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6α-Fluor-12α-Halogen-Kortikoide und Verfahren zu ihrer Herstellung |
| NZ185295A (en) | 1976-10-04 | 1980-04-28 | Schering Ag | 9-chloroprednisolone derivatives and pharmaceutical compositions |
| US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4908387A (en) | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| CA2173974C (en) | 1993-10-13 | 2006-05-02 | James A. Burke | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| CA2154979A1 (en) | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
| US5910312A (en) | 1996-10-09 | 1999-06-08 | Ideal Ideas, Inc. | Acne treatment composition with vasoconstrictor |
| HK1048259B (en) | 1998-10-20 | 2005-06-03 | Omeros Corporation | Irrigation solution and method for inhibition of pain and inflammation |
| SE9901295D0 (sv) | 1999-04-13 | 1999-04-13 | Jan Hedner | Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné |
| EP1206282A1 (en) | 1999-08-19 | 2002-05-22 | Lavipharm S.A. | Film forming polymers, methods of use, and devices and applications thereof |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| WO2002005853A2 (en) | 2000-07-14 | 2002-01-24 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| DK1761266T3 (da) * | 2004-05-25 | 2013-08-05 | Galderma Pharma Sa | Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme |
| US20090061020A1 (en) | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| BRPI0822095A2 (pt) | 2007-12-21 | 2014-10-07 | Galderma Lab Inc | Método para reduzir o sangramento e/ou hematoma em um paciente |
| CA2724607A1 (en) | 2008-05-30 | 2009-12-31 | Fairfield Clinical Trials, Llc | Method and composition for skin inflammation and discoloration |
| WO2009152344A2 (en) * | 2008-06-11 | 2009-12-17 | Comgenrx, Inc. | Combination therapy using phosphodiesterase inhibitors |
| PL2493474T3 (pl) | 2009-10-30 | 2020-03-31 | Intratus, Inc. | Sposoby i kompozycje do podtrzymywanego dostarczania leków |
| AU2011231543B2 (en) | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
-
2012
- 2012-10-12 MX MX2014004383A patent/MX2014004383A/es unknown
- 2012-10-12 US US14/344,099 patent/US9744168B2/en not_active Expired - Fee Related
- 2012-10-12 AU AU2012324543A patent/AU2012324543B2/en not_active Expired - Fee Related
- 2012-10-12 JP JP2014536349A patent/JP2014530846A/ja active Pending
- 2012-10-12 RU RU2014119879/15A patent/RU2014119879A/ru not_active Application Discontinuation
- 2012-10-12 CA CA2850273A patent/CA2850273A1/en not_active Abandoned
- 2012-10-12 CN CN201280051534.6A patent/CN103889417A/zh active Pending
- 2012-10-12 WO PCT/IB2012/002500 patent/WO2013057579A2/en not_active Ceased
- 2012-10-12 KR KR1020147011912A patent/KR20140091543A/ko not_active Withdrawn
- 2012-10-12 PH PH1/2014/500783A patent/PH12014500783A1/en unknown
- 2012-10-12 EP EP12821025.9A patent/EP2768502A2/en not_active Withdrawn
- 2012-10-12 BR BR112014009210A patent/BR112014009210A2/pt not_active IP Right Cessation
-
2014
- 2014-03-31 IL IL231820A patent/IL231820A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| CL2013001943A1 (es) | Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma. | |
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| JP2016518337A5 (enExample) | ||
| BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
| SMT201600040B (it) | Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica | |
| CL2013002007A1 (es) | Compuesto polimorfo (s)-3-(1-(9h-purin-6-ilamino)etil)-8-cloro-2-fenilisoquinolin-1-(2h)-ona de formas b-j, amorfa, sal, solvato o hidrato del mismo; mezclas de estos compuestos; metodo para preparar el polimorfo de forma c; composicion farmaceutica; metodo de tratamiento; uso para el tratamiento de un trastorno mediado por pi3k. | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| JP2013532687A5 (enExample) | ||
| MY158339A (en) | DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | |
| JP2011006431A5 (enExample) | ||
| CL2013002552A1 (es) | Uso de una combinación de un compuesto derivado de 3-fenil-2-[1-(9h-purin-6-ilamino)alquil]quinazolin-4-ona y uno o más agentes terapéuticos seleccionados entre bendamustina, rituximab, lenalidomida y ofatumumab, para el tratamiento del cáncer. | |
| CL2013001885A1 (es) | Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08). | |
| CY1119328T1 (el) | Αναστολεας ανοχης σε αναλγητικα | |
| ECSP11011136A (es) | Compuestos útiles para inhibir chk1 | |
| UY35006A (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| CL2012001349A1 (es) | Uso de una composicion farmaceutica que comprende telmisartan para el tratamiento de hipertension sistemica en gatos ( div. sol. 2897-07). | |
| JP2014530846A5 (enExample) | ||
| JP2013538853A5 (enExample) | ||
| AR083528A1 (es) | Analogos de peptido insulinotropico dependiente de glucosa | |
| LT3456340T (lt) | Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| BR112014001425A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo | |
| RU2014119879A (ru) | Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 |